—
Swiss credit: Mediobanca goes to NEUTRAL (outperform) until 1.30pm.
Nestle: Goldman Sachs is BUY up to CHF 121 (123) Fr. Estimated reductions due to the weak dollar. Credit Suisse will stay with NEUTRAL up to CHF 105 (102). The board of directors will buy shares worth CHF 250,000.
AMS: Despite yesterday’s speculation for OUTPERFORM, Credit Suisse remains up to CHF 25. Is a little more cautious than before. Mirabaud Securities speaks of an overreaction on the stock exchange.
Arbonia: Expects slightly lower annual sales due to currency effects. Op. Profit of around CHF 150 million expected. ZKB wants to increase op. Profit estimates by up to 13 percent. Stick with MARKET WEIGHTS.
Bossard: Stifel goes to BUY (Hold) up to 200 Fr.
Clariant: Commits former AkzoNobel man Conrad Keijzer as head of the company. Industry insiders say it could mean going it alone strategically. ZKB judges positively, is for OVERWEIGHT.
Lindt & Sprüngli: Kepler Cheuvreux no longer negative. Increased to HOLD (Reduce) to 85,000 (65,000) Fr.
Novartis: Leukemia drug asciminib shows superiority in comparative studies.
Roche: Will with me in the future Lonza-Partner Modern work together in Covid diagnostics.
Schweiter: UBS is for NEUTRAL up to 1350 (118) Fr. Increases earnings estimates by up to 20 percent.
SFS Group: Smaller share placement by the Stadler family in connection with a derivative transaction.
SGS: Merrill Lynch increases to 2420 (2100) Fr. with UNDERPERFORM. Gives British rival Intertek the privilege.
Sika: Stifel puts shares for Straumann on the SWISS FOCUS LIST. Is for BUY up to 290 Fr.
Sunrise Communications: Barclays cuts to EQUAL-WEIGHT (Overweight) to 110 Fr. Better late than never.
Derivatives: Early trades are limited to the Long Mini-Futures MAMBMV AMS and the CLNRJB call warrant Clariant.
–
